#HIV5

3 Apr 2026

Lenacapavir rollout in Zimbabwe faces diplomatic dispute

Zimbabwe has begun a phase one rollout of the long-acting HIV prevention drug lenacapavir. A diplomatic dispute with the US has put future doses at risk, and health officials warn that delays could cause drug resistance.

Read

Photo by Radission US, Unsplash

30 Dec 2025

Telemedicine now delivers a growing share of PrEP in the US

A national analysis finds that nearly 20% of US PrEP users received medication by telemedicine in 2024, a large rise from under 1% in 2019. The study used national prescription counts and data from a telePrEP provider.

Level

Read

2 Oct 2025

Affordable twice-yearly HIV injection lenacapavir to reach 120 countries

Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.

Level

Read

30 Sept 2025

US unveils America First Global Health Strategy

On 18 September the US announced the America First Global Health Strategy. It prioritises US safety and innovation, asks low- and middle-income countries to co-invest, and has raised concerns from experts and global health groups.

Level

Read

21 Oct 2024

Lenacapavir: six-month injection to prevent HIV

Lenacapavir is a long-acting injectable for HIV prevention that is given every six months. Experts say its effect will depend on price, supply and how quickly approvals and generic production reach countries in Africa and beyond.

Level

Read

No more articles